journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/30217601/comment-on-erlotinib-in-combination-with-bevacizumab-has-potential-benefit-in-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#1
LETTER
Ran Xu, Jing Zhu
No abstract text is available yet for this article.
September 7, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30193907/reply-to-dickhoff-et-al-from-authors-of-induction-chemoradiotherapy-versus-chemotherapy-alone-for-superior-sulcus-lung-cancer
#2
LETTER
Lary A Robinson, Tawee Tanvetyanon, Deanna Grubbs, Scott Antonia, Ben Creelan, Jacques Fontaine, Eric Toloza, Robert Keenan, Thomas Dilling, Craig W Stevens, K Eric Sommers, Frank Vrionis
No abstract text is available yet for this article.
August 29, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30144954/in-regard-to-robinson-et-al-induction-chemoradiotherapy-versus-chemotherapy-alone-for-superior-sulcus-lung-cancer
#3
LETTER
C Dickhoff, M Dahele
No abstract text is available yet for this article.
August 16, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30119925/adjuvant-treatment-patterns-and-outcomes-in-patients-with-stage-ib-iiia-non-small-cell-lung-cancer-in-france-germany-and-the-united-kingdom-based-on-the-lucabis-burden-of-illness-study
#4
Christos Chouaid, Sarah Danson, Stefan Andreas, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Mark Price, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Sorrel Wolowacz, James A Kaye, Ilias Kontoudis
OBJECTIVES: To inform health-technology assessments of new adjuvant treatments, we describe treatment patterns in patients with complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC) in France, Germany, and the United Kingdom (UK). MATERIALS AND METHODS: Data were collected via medical record abstraction. Patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC, diagnosed between 01 January 2009 and 31 December 2011. Median follow-up was 26 months...
August 10, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089603/common-cancer-driver-mutations-and-their-association-with-abnormally-methylated-genes-in-lung-adenocarcinoma-from-never-smokers
#5
Mathewos Tessema, Michael R Rossi, Maria A Picchi, Christin M Yingling, Yong Lin, Suresh S Ramalingam, Steven A Belinsky
OBJECTIVES: Lung adenocarcinoma in never-smokers accounts for 15-20% of all lung cancer. Although targetable mutations are more prevalent in these tumors, the biological and clinical importance of coexisting and/or mutually exclusive abnormalities is just emerging. This study evaluates the relationships between common genetic and epigenetic aberrations in these tumors. MATERIALS AND METHODS: Next-generation sequencing was employed to screen 20 commonly mutated cancer-driver genes in 112 lung adenocarcinomas from never-smokers...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089602/randomized-phase-ii-study-of-fulvestrant-and-erlotinib-compared-with-erlotinib-alone-in-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer
#6
Edward B Garon, Jill M Siegfried, Laura P Stabile, Patricia A Young, Diana C Marquez-Garban, David J Park, Ravi Patel, Eddie H Hu, Saeed Sadeghi, Rupesh J Parikh, Karen L Reckamp, Brad Adams, Robert M Elashoff, David Elashoff, Tristan Grogan, He-Jing Wang, Sanja Dacic, Meghan Brennan, Yacgley Valdes, Simon Davenport, Steven M Dubinett, Michael F Press, Dennis J Slamon, Richard J Pietras
OBJECTIVES: This open-label, randomized phase II trial evaluated antitumor efficacy of an antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor (EGFR) inhibitor, erlotinib, in advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Patients with advanced or metastatic NSCLC, ECOG 0-2, previous chemotherapy unless patient refusal, and no prior EGFR-directed therapy were randomized 2:1 to erlotinib 150 mg oral daily plus 500 mg intramuscular fulvestrant on day 1, 15, 29 and every 28 days thereafter or erlotinib alone 150 mg oral daily...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089601/case-control-study-of-pd-1-pd-l1-and-b7-h3-expression-in-lung-cancer-patients-with-and-without-human-immunodeficiency-virus-hiv-infection
#7
Katherine A Scilla, Dan P Zandberg, Søren M Bentzen, Candace Mainor, Jonathon Heath, Olga B Ioffe, Ashley L Cellini, Martin J Edelman, David J Riedel, Josephine L Feliciano
OBJECTIVE: Co-signaling molecules PD-L1, B7-H3, and PD-1 play a key role in cancer immunology. There are limited but emerging data on expression of these molecules in HIV-infected lung cancer patients. MATERIALS AND METHODS: We reviewed archived lung cancer tissue samples from HIV-infected cases (n = 13) and HIV-uninfected controls (n = 13) from 2001-2015. Cases and controls were matched by histology and stage. Immunostained tumor sections were analyzed for percent of tumor cells expressing PD-L1 and B7-H3, and percent of tumor infiltrating immune cells (TII) expressing PD-1 and PD-L1...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089600/next-generation-sequencing-reveals-a-novel-alk-g1128a-mutation-resistant-to-crizotinib-in-an-alk-rearranged-nsclc-patient
#8
Xinghao Ai, Xiaomin Niu, Lianpeng Chang, Rongrong Chen, Sai-Hong Ignatius Ou, Shun Lu
OBJECTIVE: Acquired secondary mutations in the anaplastic lymphoma kinase (ALK) gene have been identified in ALK-rearranged non-small cell lung cancer (NSCLC) patients who are resistant to treatment with the ALK inhibitor crizotinib. We sought to uncover novel mutations that contribute to resistance in these patients. MATERIALS AND METHODS: Following clinical diagnosis and development of crizotinib treatment resistance, tissue and ctDNA samples were obtained from the 60-year-old patient and subjected to next-generation sequencing for identification of mutations contributing to drug resistance...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089599/clinicopathological-implications-of-met-exon-14-mutations-in-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#9
REVIEW
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo
MET exon 14 mutation is an uncommon genomic alteration in non-small cell lung cancer (NSCLC). This meta-analysis aimed at investigating the clinicopathological and prognostic features of NSCLCs with MET exon 14 mutation in comparison with other genetic events. We performed a search in four electronic databases including PubMed, Web of Science, Scopus, and Virtual Health Library from inception to February 2018. Relevant data were extracted and pooled into odds ratio (OR), mean differences (MD), and corresponding 95% confidence intervals (CI) using the random-effect model...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089598/the-prognostic-value-of-tp53-and-its-correlation-with-egfr-mutation-in-advanced-non-small-cell-lung-cancer-an-analysis-based-on-cbioportal-data-base
#10
Xiao-Dong Jiao, Bao-Dong Qin, Pu You, Jian Cai, Yuan-Sheng Zang
OBJECTIVES: The prognostic value of TP53 in advanced non-small-cell lung cancer (NSCLC) is unclear. Whether different mutated exon has different prognostic value is unknown. We sought to reveal the prognostic value of TP53 in advanced NSCLC, as well as the correlation with EGFR mutation. MATERIALS AND METHODS: Information regarding TP53 and EGFR alterations and patients' survival time in advanced NSCLC was downloaded from the Cancer Genome Atlas Database. We further subdivided TP53 and EGFR mutation into subgroups based on different mutation exon, and then evaluated the distribution of different mutation exon as well as the prognostic value...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089597/factors-associated-with-gene-aberration-test-status-and-treatment-decision-in-patients-with-unresectable-stage-iiib-iv-nonsquamous-non-small-cell-lung-cancer-a-multicenter-survey-in-china-ctong-1506
#11
Yong Song, Qing Zhou, Xin Zhang, Gong-Yan Chen, Dian-Sheng Zhong, Zhuang Yu, Ping Yu, Yi-Ping Zhang, Jian-Hua Chen, Yi Hu, Guo-Sheng Feng, Xia Song, Qiang Shi, Lu Lu Yang, Luan Di Yao, Lu Jing Zhan, Fan Yang, Yi-Long Wu
OBJECTIVES: This study investigated factors associated with (i) the likelihood of receiving a gene aberration test and (ii) the choice of treatment between chemotherapy and targeted therapy in patients with non-small cell lung cancer (NSCLC) in China. MATERIALS AND METHODS: This cross-sectional study analyzed data previously extracted from the medical charts of patients with unresectable Stage IIIB/IV nonsquamous NSCLC discharged from one of 12 tertiary hospitals in China between August 2015 and March 2016...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089596/pneumonitis-in-advanced-non-small-cell-lung-cancer-patients-treated-with-egfr-tyrosine-kinase-inhibitor-meta-analysis-of-153-cohorts-with-15-713-patients-meta-analysis-of-incidence-and-risk-factors-of-egfr-tki-pneumonitis-in-nsclc
#12
Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino
PURPOSE: Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in clinical trials of EGFR-TKI published in 2003-2017, and performed subgroups analyses to identity predisposing factors. METHODS: Ovid-MEDLINE and EMBASE search up to 4/17/17 using the keywords, "erlotinib", "gefitinib", "afatinib", "osimertinib", and "lung cancer", resulted in a total of 153 eligible trial cohorts with 15,713 advanced NSCLC patients treated with EGFR-TKI...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089595/computed-tomography-characteristics-of-lung-adenocarcinomas-with-epidermal-growth-factor-receptor-mutation-a-propensity-score-matching-study
#13
Young Joo Suh, Hyun-Ju Lee, Young Jae Kim, Kwang Gi Kim, Heekyung Kim, Yoon Kyung Jeon, Young Tae Kim
OBJECTIVES: We investigated the relationship between computed tomography (CT) characteristics and epidermal growth factor receptor (EGFR) mutations in a large Asian cohort who received surgical resection of invasive lung adenocarcinoma. MATERIALS AND METHODS: We retrospectively included 864 patients (524 with EGFR mutation and 340 with EGFR wild-type) who received surgical resections for invasive lung adenocarcinomas. After applying propensity score matching, 312 patients with mutated EGFR were matched with 312 patients with wild-type EGFR...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089594/two-plasma-microrna-panels-for-diagnosis-and-subtype-discrimination-of-lung-cancer
#14
Shaohua Lu, Hui Kong, Yingyong Hou, Di Ge, Wei Huang, Jiaxian Ou, Dawei Yang, Li Zhang, Guoming Wu, Yong Song, Xiaoju Zhang, Changwen Zhai, Qun Wang, Hongguang Zhu, Ying Wu, Chunxue Bai
OBJECTIVES: Early and accurate diagnosis of lung cancer is crucial for effective treatment. This study aimed to identify plasma microRNAs for diagnosis of lung cancer and for further discrimination of small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Plasma microRNA expression was investigated using three independent cohorts including 1132 participants recruited between October 2008 and September 2014 from five medical centers...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089593/inhibition-of-igf1r-enhances-2-deoxyglucose-in-the-treatment-of-non-small-cell-lung-cancer
#15
Fakeng Liu, Yuan Liu, Xiuju Liu, Kaisheng Mao, Diansheng Zhong, Adam I Marcus, Fadlo R Khuri, Shi-Yong Sun, Yulong He, Wei Zhou
OBJECTIVE: We previously postulated that 2-deoxyglucose (2-DG) activates multiple pro-survival pathways through IGF1R to negate its inhibitory effect on glycolysis. Here, we evaluated whether IGF1R inhibitor synergizes with 2-DG to impede the growth of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The activation of IGF1R signaling was assessed by the phosphorylation of IGF1R and its downstream target AKT using immunoblot. Drug dose response and combination index analyses were carried out according to the method of Chou and Talalay...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089592/comparison-of-glut-1-sglt-1-and-sglt-2-expression-in-false-negative-and-true-positive-lymph-nodes-during-the-18-f-fdg-pet-ct-mediastinal-nodal-staging-of-non-small-cell-lung-cancer
#16
Naohiro Taira, Eriko Atsumi, Saori Nakachi, Reika Takamatsu, Tomofumi Yohena, Hidenori Kawasaki, Tsutomu Kawabata, Naoki Yoshimi
INTRODUCTION: Although positron emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated with computed tomography (CT), (18 F-FDG PET/CT), has recently improved the mediastinal nodal staging of non-small cell lung cancer (NSCLC), this method can show false negativity. We immunohistochemically investigated the expression of glucose transporters (GLUT-1, SGLT-1, and SGLT-2) in false negative and true positive mediastinal nodes via 18 F-FDG PET/CT. METHODS: We investigated patients with clinically-diagnosed N0/pathological N2 diseases and patients with clinically-diagnosed N2/pathological N2 disease...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089591/the-prognostic-effect-of-single-and-multiple-cancer-related-somatic-mutations-in-resected-non-small-cell-lung-cancer
#17
Kevin Jao, Pascale Tomasini, Suzanne Kamel-Reid, Gregorz J Korpanty, Céline Mascaux, Shingo Sakashita, Catherine Labbé, Natasha B Leighl, Geoffrey Liu, Ronald Feld, Penelope A Bradbury, David M Hwang, Melania Pintilie, Ming-Sound Tsao, Frances A Shepherd
INTRODUCTION: Somatic mutations are becoming increasingly important biomarkers for treatment selection and outcome in patients with non-small-cell lung cancer (NSCLC). The role of multiple somatic mutations in early-stage NSCLC is unclear. METHODS: Tissue from 214 patients with resected NSCLC at the Princess Margaret Cancer Centre was analyzed by next-generation sequencing by Mi-SEQ or Sequenom multiplex platforms. Associations between mutation status, baseline patient characteristics and outcomes (disease-free survival (DFS) after surgical resection and overall survival (OS)) were investigated...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089590/first-line-pembrolizumab-in-pd-l1-positive-non-small-cell-lung-cancer-a-cost-effectiveness-analysis-from-the-uk-health-care-perspective
#18
Xiaohan Hu, Joel W Hay
BACKGROUND: Pembrolizumab has shown significant survival benefits in treating chemotherapy-naïve non-small-cell lung cancer patients (NSCLC) with increased level of PD-L1 expression. This analysis aimed to evaluate the cost-effectiveness of pembrolizumab as a first-line treatment for patients with PD-L1 positive NSCLC from the UK health care perspective. METHODS: A Markov model with progression-free, progressive disease and death states was developed. Clinical parameters were informed by the KEYNOTE-024 trial...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089589/are-working-practices-of-lung-cancer-nurse-specialists-associated-with-variation-in-peoples-receipt-of-anticancer-therapy
#19
Iain Stewart, Aamir Khakwani, Richard B Hubbard, Paul Beckett, Diana Borthwick, Angela Tod, Alison Leary, Laila J Tata
OBJECTIVES: Treatment choices for people with lung cancer may be influenced by contact and engagement with lung cancer nurse specialists (LCNSs). We investigated how service factors, LCNS workload, and LCNS working practices may influence the receipt of anticancer treatment. MATERIALS AND METHODS: English National Lung Cancer Audit data and inpatient Hospital Episode Statistics for 109,079 people with lung cancer surviving 30 days from diagnosis were linked along with LCNS workforce census data and a bespoke nationwide LCNS survey...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30089588/acute-kidney-injury-after-lung-cancer-surgery-incidence-and-clinical-relevance-predictors-and-role-of-n-terminal-pro-b-type-natriuretic-peptide
#20
Daniela Cardinale, Nicola Cosentino, Marco Moltrasio, Maria Teresa Sandri, Francesco Petrella, Alessandro Colombo, Giulia Bacchiani, Adele Tessitore, Alice Bonomi, Fabrizio Veglia, Michela Salvatici, Carlo M Cipolla, Giancarlo Marenzi, Lorenzo Spaggiari
BACKGROUND: Acute kidney injury (AKI) frequently occurs in several medical and surgical settings, and it is associated with increased morbidity and mortality. In patients undergoing lung cancer surgery, AKI has not been fully investigated. We prospectively evaluated the incidence, clinical relevance, and risk factors of AKI in patients undergoing lung cancer surgery. Moreover, we estimated the accuracy of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the prediction of AKI. METHODS: Patients undergoing lung cancer surgery were included in the study...
September 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"